The U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC) published a blog post Friday urging the U.S. Patent and Trademark Office (USPTO) to resist “misguided ‘coordination’ efforts” such as the Agency’s proposals for increasing collaboration with the Food and Drug Administration (FDA). The USPTO first published a Request for Comments in October 2022 asking the public for input on “proposed initiatives directed at bolstering the robustness and reliability of patents to incentivize and protect new and nonobvious inventions while facilitating the broader dissemination of public knowledge to promote innovation and competition.”
Recent Posts
- USPTO Fee Report: Discounts Don’t Cut It for Incentivizing New Patent Participants
- Federal Circuit Splits on Whether Toddler Tub May Infringe
- CAFC Rules Patent Applications are Considered Pre-AIA Prior Art By Filing Date, Not Publication Date
- The Biden Administration Rolls the Dice on NIH Patent Licensing
- The PTAB’s 70% All-Claims Invalidation Rate Continues to Be a Source of Concern